Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Myriad Genetics (MYGN) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Myriad Genetics (MYGN) over the last 17 years, with Q3 2025 value amounting to $167.1 million.

  • Myriad Genetics' Operating Expenses fell 159.01% to $167.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 billion, marking a year-over-year increase of 9604.46%. This contributed to the annual value of $708.9 million for FY2024, which is 845.82% down from last year.
  • As of Q3 2025, Myriad Genetics' Operating Expenses stood at $167.1 million, which was down 159.01% from $481.0 million recorded in Q2 2025.
  • In the past 5 years, Myriad Genetics' Operating Expenses registered a high of $481.0 million during Q2 2025, and its lowest value of -$8.2 million during Q4 2023.
  • Over the past 5 years, Myriad Genetics' median Operating Expenses value was $197.1 million (recorded in 2022), while the average stood at $199.6 million.
  • Its Operating Expenses has fluctuated over the past 5 years, first crashed by 12928.57% in 2023, then skyrocketed by 241585.37% in 2024.
  • Myriad Genetics' Operating Expenses (Quarter) stood at $203.9 million in 2021, then plummeted by 86.27% to $28.0 million in 2022, then crashed by 129.29% to -$8.2 million in 2023, then soared by 2415.85% to $189.9 million in 2024, then fell by 12.01% to $167.1 million in 2025.
  • Its last three reported values are $167.1 million in Q3 2025, $481.0 million for Q2 2025, and $163.2 million during Q1 2025.